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Introduction
The antiphospholipid antibody syndrome (APS) is a mul-
tisystemic autoimmune disease characterized by throm-
boembolic events, pregnancy morbidity, hematologic,
dermatologic, neurologic and other manifestations in the
presence of elevated titers of antiphospholipid antibodies
(aPL). In recent years, APS has been increasingly recog-
nized in various pediatric autoimmune and nonautoim-
mune diseases, but the relatively low prevalence and
heterogeneity of APS in childhood made it very difficult
to study in a systematic way.
Objective
To evaluate the prevalence of thrombotic and nonthrom-
botic clinical manifestations in children with positive aPL
and determine the long-term outcome of children with
APS.
Methods
A retrospective study with longitudinal follow-up of an
unselected group of children who tested positive for at
least one aPL subtype (aCL, anti-b2GPI and/or LA) was
conducted for assessment of the prevalence of clinical fea-
tures associated with aPL in children. Testing for aPL was
requested by treating physicians given the clinical suspi-
cion of aPL-related clinical manifestations. Data from the
European registry extended internationally of pediatric
patients with APS (Ped-APS Registry) were used for
assessment of the long-term outcome of children with
APS. To be eligible for enrollment the patient must meet
the preliminary criteria for the classification of pediatric
APS and the onset of APS must have occurred prior to
the patient’s 18th birthday.
Results
A total of 159 patients who tested positive for at least one
aPL subtype (aCL, anti-b2GPI and/or LA) at the time of
or within the first three months after the disease presenta-
tion were enrolled. There were 98 (62%) females and 61
(38%) males with mean age at disease presentation 11.4
years (range: 1-18 years). Mean follow-up period was 6.2
years. During this period 25 (16%) patients had thrombotic
event (16 venous and 9 arterial), 48 (30%) patients devel-
oped hematological manifestations, 25 (16%) patients non-
thrombotic neurological manifestations, 19 (12%) patients
skin manifestations and 5 (3%) patients cardiac valve
disease. Two out of 25 (8%) patients with thrombosis had
recurrent thrombotic event. Underlying systemic autoim-
mune disease was identified in 55 (35%) of patients.
The clinical characteristics and outcome was compared
with 140 children with APS included in the Ped-APS Reg-
istry. Venous thrombosis occurred in 86 (61%), arterial
thrombosis in 43 (31%), small vessel thrombosis in 7 (5%)
and mixed arterial and venous thrombosis in 4 (3%)
patients. Associated non-thrombotic clinical manifesta-
tions included hematological manifestations (39%), skin
disorders (19%) and non-thrombotic neurological manifes-
tations (16%). Mean follow-up time from the time of APS
diagnosis was 6.1 years. Recurrent thrombosis was
observed in 19% of pediatric patients with initial venous
thrombosis and 21% of patients with initial arterial throm-
bosis. Sixty-eight (49%) patients included in the Ped-APS
Registry had underlying autoimmune disease.
Discussion
Nonthrombotic clinical manifestations were more fre-
quent than thrombotic events (16%) in an unselected
group of children with positive aPL. Children with APS
have significantly higher thrombosis recurrence rates as
compared with adult APS patients.
Department of Allergology, Rheumatology and Clinical Immunology,
Children’s Hospital, University Medical Center Ljubljana, Ljubljana, Slovenia
Avcin Pediatric Rheumatology 2013, 11(Suppl 2):I13
http://www.ped-rheum.com/content/11/S2/I13
© 2013 Avcin; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Disclosure of interest
None declared.
Published: 5 December 2013
doi:10.1186/1546-0096-11-S2-I13
Cite this article as: Avcin: PReS13-SPK-1592: Pediatric aspects of
antiphospholipid syndrome. Pediatric Rheumatology 2013 11(Suppl 2):I13.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Avcin Pediatric Rheumatology 2013, 11(Suppl 2):I13
http://www.ped-rheum.com/content/11/S2/I13
Page 2 of 2
